A class action lawsuit has been initiated against Corcept Therapeutics Incorporated, alleging the company made material misrepresentations regarding clinical evidence supporting its relacorilant drug candidate. The FDA issued a Complete Response Letter rejecting the application, citing insufficient efficacy data to support approval. Following the regulatory setback, Corcept's stock price declined more than 50 percent.
According to the complaint, Corcept failed to adequately disclose to investors that the FDA had raised significant concerns about the clinical development program during pre-submission review meetings. These undisclosed regulatory interactions allegedly contradicted the company's public statements regarding the strength of clinical evidence supporting the candidate drug. The lawsuit seeks to represent investors who sustained losses during the period of alleged misrepresentation.
The litigation represents a critical juncture for shareholders who experienced substantial declines in their investment value following the FDA's rejection decision. Investors with significant positions in Corcept stock during the relevant period may be eligible to participate in the class action proceedings.